12
Participants
Start Date
April 30, 2015
Primary Completion Date
February 28, 2019
Study Completion Date
February 28, 2019
5-fraction stereotactic body radiation therapy
"The investigators expect to need a maximum of 3 dose levels investigating dose to the area at risk of involved resection lines and to the tumour bed to assess the tolerability of SBRT in this setting.~Patient entry will commence at level 1. There is the option to de-escalate to Level -1 should 2 or more DLTs be observed at the starting level. SBRT will not be escalated above level 3.~Level -1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV\_R) 8Gy/# (total dose 40Gy)~Level 1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV\_R) 9Gy/# (total dose 45Gy)~Level 2:~Tumour (PTV) 6.5Gy/# (total dose 32.5Gy). Area at risk of R1 (PTV\_R) 9.5Gy/# (total dose 47.5Gy)~Level 3:~Tumour (PTV) 7Gy/# (total dose 35Gy). Area at risk of R1 (PTV\_R) 10Gy/# (total dose 50Gy)"
The Beatson West of Scotland Cancer Centre, Glasgow
St James' Hospital, Leeds
Northern Centre for Cancer Care, The Freeman Hospital, Newcastle
City Hospital, Nottingham
The Churchill Hospital, Oxford University Hospitals Trust, Oxford
Oncology Clinical Trials Office
UNKNOWN
Centre for Statistics in Medicine
OTHER
CRUK/MRC Oxford Institute for Radiation Oncology
UNKNOWN
University of Leeds
OTHER
University of Oxford
OTHER